Coustan-Smith E - Search Results

1

XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.

Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. Koehler M, et al. Bone Marrow Transplant. 1994 May;13(5):571-5. Bone Marrow Transplant. 1994. PMID: 7519937

2

The definition of remission in acute leukemia with immunologic techniques.

Campana D, Coustan-Smith E, Behm FG. Campana D, et al. Bone Marrow Transplant. 1991 Dec;8(6):429-37. Bone Marrow Transplant. 1991. PMID: 1790423 Review.

3

Differential expression of MHC class II antigens in chronic B-cell disorders.

Drexler HG, Gignac SM, Brenner MK, Coustan-Smith E, Janossy G, Hoffbrand AV. Drexler HG, et al. Clin Exp Immunol. 1988 Feb;71(2):217-23. Clin Exp Immunol. 1988. PMID: 2450706 Free PMC article.

4

Synergistic action of calcium ionophore A23187 and phorbol ester TPA on B-chronic lymphocytic leukemia cells.

Drexler HG, Brenner MK, Coustan-Smith E, Wickremasinghe RG, Hoffbrand AV. Drexler HG, et al. Blood. 1987 Nov;70(5):1536-42. Blood. 1987. PMID: 3117134 Free article.

5

Analysis of signal transduction in B chronic lymphocytic leukemia cells.

Drexler HG, Brenner MK, Coustan-Smith E, Gignac SM, Hoffbrand AV. Drexler HG, et al. Blood. 1988 May;71(5):1461-9. Blood. 1988. PMID: 3129049 Free article.

6

N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia.

Coustan-Smith E, Behm FG, Hurwitz CA, Rivera GK, Campana D. Coustan-Smith E, et al. Leukemia. 1993 Jun;7(6):853-8. Leukemia. 1993. PMID: 7684798

7

Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia.

Kumagai M, Manabe A, Coustan-Smith E, Blakley RL, Beck WT, Santana VM, Behm FG, Raimondi SC, Campana D. Kumagai M, et al. Leukemia. 1994 Jul;8(7):1116-23. Leukemia. 1994. PMID: 7913512

8

Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.

Foreman NK, Rill DR, Coustan-Smith E, Douglass EC, Brenner MK. Foreman NK, et al. Br J Cancer. 1993 May;67(5):933-8. doi: 10.1038/bjc.1993.173. Br J Cancer. 1993. PMID: 8494726 Free PMC article.

9

Human B-cell progenitors and bone marrow microenvironment.

Campana D, Coustan-Smith E, Manabe A, Kumagai M, Murti KG, Silvennoinen O, Nishigaki H, Kitanaka A, Ito C. Campana D, et al. Hum Cell. 1996 Dec;9(4):317-22. Hum Cell. 1996. PMID: 9183664 Review.

10

Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma.

Bowman LC, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Brenner M. Bowman LC, et al. Hum Gene Ther. 1998 Jun 10;9(9):1303-11. doi: 10.1089/hum.1998.9.9-1303. Hum Gene Ther. 1998. PMID: 9650615

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters